NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a global biopharmaceutical company, has declared a quarterly cash dividend of $0.42 per share for the fourth quarter of 2024. This dividend is payable on December 2, 2024, to shareholders on record as of the close of business on November 8, 2024. The upcoming dividend marks the 344th consecutive quarterly payment by the company, underscoring its long-standing commitment to return value to shareholders.
The announcement reflects Pfizer's position as a leading entity in the healthcare sector, with a history spanning 175 years. The company's focus on developing innovative medicines and vaccines has been central to its mission of improving the health and well-being of people around the world. Pfizer's approach combines scientific research with accessibility, aiming to provide high-quality, safe, and effective healthcare products.
As part of its corporate responsibility, Pfizer collaborates with healthcare providers, governments, and communities to enhance healthcare access globally. The company's dedication to advancing treatments for some of the most challenging diseases continues to be a core aspect of its operations.
Pfizer's financial decisions, including dividend declarations, are closely watched by investors as indicators of the company's performance and stability. The regular payment of dividends is often seen as a sign of a company's financial health and its ability to generate consistent cash flow.
The information regarding the dividend declaration is based on a press release statement from Pfizer Inc. This development is pertinent to investors tracking Pfizer's stock performance and to those interested in the company's financial practices. Pfizer's commitment to shareholder returns through dividends is part of its broader financial strategy, which is monitored by investors for insights into the company's long-term prospects.
For further information on Pfizer's financial decisions and healthcare contributions, the company regularly updates important information for investors on its website.
In other recent news, GSK and Pfizer are experiencing a significant drop in U.S. sales of their respiratory syncytial virus (RSV) vaccines, Arexvy and Abrysvo respectively. This decline is due to regulatory decisions narrowing the eligible age group for vaccination. Despite this, GSK anticipates strong growth for Arexvy, expecting peak year sales of £3 billion ($3.92 billion). Pfizer's CEO, Albert Bourla, also remains optimistic about Abrysvo's performance in the U.S. market.
In 2023, GSK's Arexvy generated £1.2 billion ($1.57 billion) in sales, while Pfizer's Abrysvo reached $890 million. Analysts predict a slight dip in GSK's sales this year, while Pfizer's sales are expected to rise nearly 40% to $1.2 billion.
Activist investment firm Starboard Value has reportedly acquired a stake of approximately $1 billion in Pfizer and is set to meet with Pfizer's CEO to discuss potential changes to improve the company's performance.
Financial research firm CFRA has revised upwards the earnings forecasts for Pfizer and upgraded the price target for Pfizer shares to $31.00. TD Cowen sustained its Hold rating on Pfizer shares, acknowledging new cost initiatives that are likely to enhance the company's profit and loss statement in the mid-term. However, the firm also noted significant challenges, including competitive pressures and unimpressive performance of new drugs.
InvestingPro Insights
Pfizer's latest dividend declaration aligns with its strong track record of shareholder returns. According to InvestingPro data, the company currently offers a substantial dividend yield of 5.76%, making it an attractive option for income-focused investors. This high yield is complemented by Pfizer's consistent dividend growth, with an InvestingPro Tip noting that the company has raised its dividend for 13 consecutive years.
Despite recent challenges, including a revenue decline of 29.65% over the last twelve months, Pfizer maintains a robust market capitalization of $171.02 billion. The company's commitment to innovation and global healthcare initiatives appears to be reflected in analysts' optimism. Another InvestingPro Tip suggests that net income is expected to grow this year, potentially supporting the company's ability to maintain its generous dividend policy.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips on Pfizer, providing deeper insights into the company's financial health and market position. These insights can be particularly valuable given Pfizer's status as a prominent player in the pharmaceuticals industry, as highlighted by InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.